The estimated Net Worth of Frederick J. Fritz is at least $23.1 mil dollars as of 8 April 2022. Mr. Fritz owns over 5,000 units of Imunon Inc stock worth over $23,061 and over the last 13 years he sold CLSN stock worth over $0. In addition, he makes $0 as Independent Director at Imunon Inc.
Frederick has made over 22 trades of the Imunon Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of CLSN stock worth $20,250 on 8 April 2022.
The largest trade he's ever made was buying 20,000 units of Imunon Inc stock on 7 October 2021 worth over $17,600. On average, Frederick trades about 3,652 units every 86 days since 2011. As of 8 April 2022 he still owns at least 11,766 units of Imunon Inc stock.
You can see the complete history of Mr. Fritz stock trades at the bottom of the page.
Frederick J. Fritz has been appointed as Independent Director of Celsion Corporation., since July 8, 2011. Mr. Fritz is currently the CEO and Founder of NeuroDx, a development stage diagnostic device company focused on the neurosurgery market. Mr. Fritz joined NeuroDx from Valeo Medical, a biotech company he founded in 2003 to develop the world's first non-invasive diagnostic test for endometriosis. Prior to that, Mr. Fritz was President and CEO of Songbird Hearing, a medical device company spun out of Sarnoff Corporation. Mr. Fritz began his career in marketing management and new product development. He joined Schering Plough's Wesley Jessen in 1985 as VP Marketing and Sales in 1986. He was promoted to general manager of Schering's Over the Counter pharmaceutical business in 1988 and of the podiatric products business in 1990. He was President of Coleman North America from 1995-1997. Mr. Fritz holds a Bachelor’s degree in engineering (summa cum laude) from University of Illinois and an MBA degree from Harvard University.
Frederick Fritz is 64, he's been the Independent Director of Imunon Inc since 2011. There are 3 older and 8 younger executives at Imunon Inc. The oldest executive at Imunon Inc is Michael H. Tardugno, 70, who is the Exec. Chairman, Pres & CEO.
Frederick's mailing address filed with the SEC is C/O CELSION CORPORATION, 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648.
Over the last 17 years, insiders at Imunon Inc have traded over $895,739 worth of Imunon Inc stock and bought 973,579 units worth $2,229,348 . The most active insiders traders include Gary W Pace, Max Link y Sean F. Moran. On average, Imunon Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,407. The most recent stock trade was executed by Michael H Tardugno on 12 April 2022, trading 4,000 units of CLSN stock currently worth $14,120.
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Imunon Inc executives and other stock owners filed with the SEC include: